Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
about
Advances in liver transplantation allocation systemsMultimodal treatment of hepatocellular carcinoma on cirrhosis: an updateManagement of "very early" hepatocellular carcinoma on cirrhotic patientsToward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinomaExcess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.Waiting time and explant pathology in transplant recipients with hepatocellular carcinoma: a novel study using national data.Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluationReframing the impact of combined heart-liver allocation on liver transplant wait-list candidates.Standardizing MELD Exceptions: Current Challenges and Future DirectionsMELD exceptions for portopulmonary hypertension: current policy and future implementation.Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation.Management of Hepatocellular Carcinoma: Current Status and Future Directions.Early post-transplant survival: Interaction of MELD score and hospitalization status.Impact of MELD Allocation System on Waiting List and Early Post-Liver Transplant Mortality.Effects of the Share 35 Rule on Waitlist and Liver Transplantation Outcomes for Patients with Hepatocellular Carcinoma.Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.Comparison of two equivalent MELD scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.Liver transplant center variability in accepting organ offers and its impact on patient survival.COMPARATIVE STUDY ON LIVER TRANSPLANTATION WITH AND WITHOUT HEPATOCELLULAR CARCINOMA WITH CIRRHOSIS: ANALYSIS OF MELD, WAITING TIME AND SURVIVAL.Underreporting of liver transplant waitlist removals due to death or clinical deterioration: results at four major centers.HCC patients suffer less from geographic differences in organ availabilitySquaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach.Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma.Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.Patient selection for liver transplantation.The promise of organ and tissue preservation to transform medicine.Transplant-related survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma.Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis.Patients With Hepatocellular Carcinoma Have Highest Rates of Wait-listing for Liver Transplantation Among Patients With End-Stage Liver Disease.Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease.MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.The Use of Donation After Cardiac Death Allografts Does Not Increase Recurrence of Hepatocellular Carcinoma.Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach.Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment.The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States.
P2860
Q26766076-BB9C78E9-5A42-4F49-A49F-C96564433BBEQ26825172-F690B9D6-45C1-46EE-8AA2-58C663BB1017Q26864406-DD50C814-4F25-4BD6-B466-480BD4F3041EQ26999411-9FD0B75F-3D77-48F7-AAF5-2D0AF5452CD7Q30458532-8B08F198-153D-4F7D-B436-C91FA8FC731EQ30829251-515711B7-1C39-4724-8A64-D66B9C669771Q33624851-607FFFDE-9DA2-4689-AFB2-D0C74C5E52BCQ34422056-A2B05AAF-395C-4F31-93E1-0D7894453D14Q34712729-4168B260-B035-4ACA-B669-2910BE33EC9AQ35120271-2BE1AA72-71D9-402C-BC8C-C518C8B7FFA9Q35384660-743B7B30-0ECB-4E63-B144-1051DA180BC5Q35771842-9E39DD48-A118-4D29-8192-5D5027F1D2FAQ35977783-51EDEDBD-E7E6-49D4-A1AC-1DC1E4DD5AB3Q36051596-62232851-9039-4728-BC7C-4E8D46D80ECCQ36259729-29875E23-126D-40D4-9537-0D7F10F4E379Q36284669-521CDD44-621D-4EC4-968B-43E6CE8150AEQ36345076-50B1567F-1A39-445B-87B7-F662812E000AQ36706307-FD486E44-F44B-41CC-8CAC-FD36FC7FEEEBQ36852128-1CBDAC4D-02E8-4146-83FE-47279EB04A21Q37025099-0EF923DB-3E0E-4F02-8736-D3252A66EEA0Q37323728-8A298ADF-1971-4CF9-9772-5383A1715388Q37348887-791E0913-2B8D-4EA4-91DC-36DD935F13E1Q37444760-167702FC-EC2C-4C62-9F28-66407A6B1594Q37611108-8198E18E-C460-493E-A1B9-CDDF277FAFA1Q37711002-C7BB2107-542E-4E89-8683-366853865D82Q38132281-B389A5D6-F74B-4C37-99FB-D42F9D8AA6D8Q38673700-5F2B9A00-A42C-46CF-A34A-AF53DED1EFEEQ39049983-39DC7092-9CF0-4F53-BFAA-C36DBA67BD89Q39179820-D8B79E30-F8DD-4FD8-B52F-D23332FBE06DQ39635570-1FCAF588-9E79-464F-9D74-2FF47F40D2B8Q39652155-AAE4712F-117B-42EC-A23E-7B7B4DE5952FQ39655966-68136F20-DFAC-4EEF-8C77-82693E46465FQ40309524-51D751F3-3CF7-4FE9-8BCB-5EF6D5D234FAQ40788363-C83E000D-564A-4AE2-B952-AE5A89004872Q41111113-B583C448-6687-4EFE-AC57-CA94B30AE845Q41397576-13C95EC7-8C22-463B-9EF6-B0445C12A23AQ41742206-27F051F1-E16F-48F9-9851-EF1CCF9B55CCQ42349921-FFFE973D-5E0D-46CB-BCFF-5D89A5FEFC23Q42667958-6C2EB0E7-6CF8-4D97-9F5C-5EEBB15249B1Q44498635-805B592F-3614-4FB3-AFE8-D1911E0CC805
P2860
Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Increasing disparity in waitli ...... hout hepatocellular carcinoma.
@ast
Increasing disparity in waitli ...... hout hepatocellular carcinoma.
@en
type
label
Increasing disparity in waitli ...... hout hepatocellular carcinoma.
@ast
Increasing disparity in waitli ...... hout hepatocellular carcinoma.
@en
prefLabel
Increasing disparity in waitli ...... hout hepatocellular carcinoma.
@ast
Increasing disparity in waitli ...... hout hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Increasing disparity in waitli ...... hout hepatocellular carcinoma.
@en
P2093
Andrew M Cameron
Benjamin French
David Goldberg
Sandy Feng
P2860
P304
P356
10.1002/LT.23394
P577
2012-04-01T00:00:00Z